Department of Thoracic Diseases, G.B. Morgagni - L. Pierantoni Hospital, Via C. Forlanini 34, 47121, Forlì, FC, Italy.
Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
BMC Pulm Med. 2019 Jan 16;19(1):16. doi: 10.1186/s12890-019-0780-3.
BACKGROUND: Standardization of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases is imminent; however, the majority of published series on cryobiopsy include a limited number of patients and are characterized by several differences in procedural technical details. METHODS: This is an observational, retrospective cohort study. Aim of the study was to suggest some sampling strategies related to transbronchial cryobiopsy in the diagnostic work-up of patients with diffuse parenchymal lung diseases. RESULTS: Six hundred ninety-nine patients with suspected diffuse parenchymal lung disease were recruited. A specific pathological diagnosis was achieved in 614/699 cases (87.8%) and a multidisciplinary diagnosis was obtained in 630/699 cases (90.1%). Diagnostic yield was significantly influenced by the number of samples taken (1 vs ≥ 2 biopsies, p < 0.005). In 60.4% of patients, biopsies were taken from one site and in 39.6% from different sites (in the same lobe or in two different lobes), with a significant increase in diagnostic yield, specifically in patients with fibrotic lung diseases (65.5% vs 93.4%, p < 0.0001). The 2.4 mm or 1.9 mm probes were used, with no differences in terms of diagnostic yield. Regarding safety, pneumothorax occurred in 19.2% and was influenced by baseline lung function; in all patients Fogarty balloon has been used and severe haemorrhage occurred in 0.7% of cases. Three patients (0.4% of cases) died within 30 days after the procedure. CONCLUSIONS: We propose some sampling strategies of cryobiopsy which seem to be associated with a higher diagnostic yield and a favorable risk/benefit ratio: sampling at least two samples in different sites, using either the 2.4 mm or the 1.9 mm probe, intubating the patients and using bronchial blockers/catheters.
背景:弥漫性实质性肺疾病的经支气管肺冷冻活检亟待标准化;然而,大多数发表的冷冻活检系列包括有限数量的患者,并且在程序技术细节上存在多种差异。
方法:这是一项观察性、回顾性队列研究。本研究的目的是提出一些与经支气管冷冻活检相关的采样策略,用于诊断弥漫性实质性肺疾病患者。
结果:共招募了 699 例疑似弥漫性实质性肺疾病患者。614/699 例(87.8%)获得了特定的病理诊断,630/699 例(90.1%)获得了多学科诊断。诊断率受取样数量的影响显著(1 次与≥2 次活检,p<0.005)。60.4%的患者在一个部位进行活检,39.6%的患者在不同部位(同一肺叶或两个不同肺叶)进行活检,诊断率显著提高,特别是在纤维化性肺疾病患者中(65.5%与 93.4%,p<0.0001)。使用了 2.4mm 或 1.9mm 的探头,诊断率没有差异。关于安全性,气胸发生率为 19.2%,与基础肺功能有关;所有患者均使用了 Fogarty 球囊,0.7%的患者发生严重出血。3 例患者(0.4%)在术后 30 天内死亡。
结论:我们提出了一些冷冻活检的采样策略,这些策略似乎与更高的诊断率和良好的风险/获益比相关:在不同部位至少采集两个样本,使用 2.4mm 或 1.9mm 探头,对患者进行插管并使用支气管阻断器/导管。
Arch Pathol Lab Med. 2020-12-1
J Bronchology Interv Pulmonol. 2016-7
Chin Med J Pulm Crit Care Med. 2025-3-7
Respirol Case Rep. 2024-8-11
Respiration. 2018-6-12
Rev Port Pneumol (2006). 2017-11-22
Expert Rev Respir Med. 2017-12
Rev Port Pneumol (2006). 2017
J Bronchology Interv Pulmonol. 2017-10
J Bronchology Interv Pulmonol. 2017-4